Shaji Kumar, MD, Mayo Clinic, discusses the July approval of linvoseltamab, a new bispecific antibody for relapsed myeloma, and how it expands treatment options for patients. He also emphasizes the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results